Tech Company Financing Transactions
NeurogesX Funding Round
Alta Partners, Arch Venture Partners and Montreux Equity Partners participated in a $35 million Series C funding round for NeurogesX. The funding round closed on 2/24/2004.
Transaction Overview
Company Name
Announced On
2/24/2004
Transaction Type
Venture Equity
Amount
$35,000,000
Round
Series C
Proceeds Purpose
This funding will allow us to complete our pivotal trials for NGX- 4010, expand our technological capabilities, acquire additional products and submit the NGX- 4010 NDA.
Company Information
Company Status
Out of Business
Industry
Biopharmaceutical
Mailing Address
999 Baker Way 200
San Mateo, CA 94404
USA
San Mateo, CA 94404
USA
Phone
Website
Email Address
Overview
NeurogesX is a privately held specialty pharmaceutical company focusing on the development novel treatments for improved relief of neuropathic pain and improved quality of life for neuropathic pain patients using advanced neuroscience insights and innovative delivery technologies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ronald Martell
Chief Financial Officer
Stephen Ghiglieri
Chief Medical Officer
Stephen Peroutka
Browse more venture capital transactions:
Prev: 2/23/2004: Mobile Cohesion venture capital transaction
Next: 2/26/2004: Sonim Technologies venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs